Sm_mary The combination of mitozantrone, methotrexate and mitomycin (3M) gives a response rate of around 50% in patients with advanced breast cancer. The predominant toxicity is haematological. In this study, previously untreated patients were given 3M with increasing doses of mitozantrone (7 -14 mg m -) with recombinant human granulocyte colony-stimulating factor (metHuG-CSF) (filgrastim) to prevent marrow toxicity. Doses administered were 7 mg m2 mitomycin i.v. 6 weekly, methotrexate i.v. 35 mg m-2 (maximum 50mg) 3 weekly and mitozantrone i.v. 3 weekly as follows: 7mg m-2, six patients (group 1); 10mg m-2, siX patients (group 2); 12 mg m-2, six patients (group 3); 14 mg m-2, six patients (group 4); all on day I for six cycles at the assigned dose. All patients received filgrastim (Amgen 0.3 mgml-') at a dose of 5zg kg-' subcutaneously daily on days 4-17 of each cycle. All treatment was given on an out-patient basis. A total of 24 patients were entered into the study. The median age was 63 years (range 48-75 The combination of mitozantrone, methotrexate and mitomycin (3M) is now extensively used in all stages of breast cancer. The 3M regimen has become popular mainly because of the easy 3 weekly administration schedule and it had equal activity to the anthrocycine-containing regimen VAC in a randomised trial (Powles et al., 1991) . In that study the response rates for both regimens were around 52%. The toxicity of 3M was acceptable, with 8% of patients (2% of courses) developing grade IV leucopenia.
Many centres have returned to the concept of high-dose therapy as consolidation in breast cancer using mobilised peripheral stem cells as rescue for the marrow toxicity. The results of randomised studies are not yet available, but these are being carried out in patients with metastatic breast cancer and in the high-risk adjuvant setting (Peters, 1993) . Highdose therapy in all tumour types has become a less toxic procedure with a mortality rate of around 4% owing to the use of penrpheral stem cell rescue instead of autologous bone marrow rescue (Shenrdan et al., 1992) .
High-dose chemotherapy with bone marrow support is not a new concept in breast cancer. A phase II study reported in 1982, in which patients with metastatic breast cancer underwent remission consolidation using high-dose melphalan, showed no advantage in terms of relapse-free survival or overall survival when compared with historical controls (Vincent et al., 1988) . High-dose chemotherapy as consolidation of remission is one form of dose intensity. Another approach is to deliver high doses of individual courses with growth factor support. This would maximise drug exposure at the time of large tumour burden and lead to rapid cell death and response. This rapid elimination of tumour cells could prevent the dissemination of micrometastases and decrease the chance of drug resistance emerging. This concept would be directly applicable to primary medical therapy for locally advanced, inoperable, non-metastatic cancer or indeed to early breast cancer for rapid downstaging (Smith et al., 1992) . Any other advantage for primary medical treatment awaits the results of randomised clinical trials which are currently being carried out.
The combination of mitozantrone, methotrexate and mitomycin (3M) is now extensively used in all stages of breast cancer. The 3M regimen has become popular mainly because of the easy 3 weekly administration schedule and it had equal activity to the anthrocycine-containing regimen VAC in a randomised trial (Powles et al., 1991) . In that study the response rates for both regimens were around 52%. The toxicity of 3M was acceptable, with 8% of patients (2% of courses) developing grade IV leucopenia.
Recombinant metHuG-CSF (filgrastim) is a glycoprotein which, in combination with other human colony-stimulating factors, controls myeloid haematopoiesis. Its main toxicities are musculoskeletal pain and changes in liver function parameters. The major study establishing the efficacy of filgrastim is a randomised trial performed in small-ell lung cancer. Patients receiving the growth factor had a statistically significant reduction in febrile neutropenic events, hospitalisation and antibiotic requirements. They had a significant reduction in the incidence and duration of severe neutropenia, and in the time to recovery from neutropenia (Crawford et al., 1991 Objective response was assessed after three courses using UICC criteria (Hayward et al., 1977 (Hb) were similar between all courses within individual patients and between the four levels. Figure 1 and Table Ill show the mean values of the leucocyte counts during the study period. There were only three documented episodes of a leucocyte count of < I x I 1PI-': one after course 1 in group 3 and two episodes after the fourth course in groups 3 and 4. Two patients in group 3 had a 1 week treatment delay because of leucopenia of <3 x 109 1-'. Other treatment delays were for either social reasons or non-haematological toxicity -one patient with stomatitis in group 1, three patients had a delay because of a holiday, one in each of groups 2, 3 and 4. In group 4 one patient had a delay because of influenza, one failed to attend and one patient had a gastrointtinal bleed. The mean platelet counts are shown in Figure 2 . The platelet count was < 50 (29 and 26) at day 14 on two occasions in one patient after the third and fifth course of chemotherapy respectively and this patient in group 4 had prolonged thrombocytopenia eventually requinrng cessation of therapy. Seven patients required a blood transfusion: three in group 1, one in group 3 and three in group 4 (one patient had a transfusion on two separate occasions). Mean haemoglobin values are shown in Figure 3 . There were four episodes of infection in four patients, two minor and two moderate (septicaemia without hypotension and chest infection). Two of the infections were at group 1 and the other two were at levels 3 and 4.
The most frequent non-haematological toxicities are reported in Table IV , and the most frequent of these are shown according to dose of mitozantrone in Table V . The main toxicities were nausea and vomiting, alopecia and lethargy. In addition, two patients in groups 3 and 4 complained of headache with the filgrastim injections, one patient had pruritus and another developed a mild skin rash. One patient in group 4 had a gastrointestial bleed and a deep venous thrombosis after the third and fifth courses of chemotherapy respectively. Nausea and vomiting occurred at all doses of mitozantrone but was grade 3 in five patients. Some degree of hair loss occurred in all levels, with half the study population requiring a wig at doses above 10 mg m-2.
Lethargy was the main toxicity, and although it occurred at all doses of mitozantrone it was the reason for stopping treatment in 2/6 patients in group 4. This was unexplained and was not due to anaemia or other cause on haematological or biochemical parameters. The lethargy resolved on This study aimed to find the maximum tolerated dose of mitozantrone in the 3M combination using filgrastim to control myelosuppression. The prolonged but reversible thrombocytopenia seen in group 4 suggests that maximum haematological tolerance had been reached. The nonhaematological toxicity seen was similar to that expected with 3M at standard dose in terms of nausea and vomiting, stomatitis, constipation, diarrhoea or neuropathy. There were few serious infections but there was a high incidence of alopecia, and severe lethargy is not usually seen with this regimen (Powles et al., 1991) .
As with other studies using increasing doses of chemotherapy with growth factor support, non-haematological toxicities became dose limiting; Bronchud et al. (1989) used doses of doxorubicin up to 150 mg m-2 and found epithelial toxicity to be dose limiting in patients with advanced breast cancer -this was an unpredicted and unusual syndrome involving the skin of the palms and soles. In our study lethargy proved to be the dose-limiting toxicity. It was profound and constant, and for that reason two patients at the higher dose of mitozantrone refused to continue treatment.
The symptom slowly regressed over a period of 6 weeks on stopping treatment.
The maximum tolerated dose of mitozantrone was 12 mg m-2 in combination with mitomycin C and methotrexate. This is not as high as has been achieved in other combinations. Doses of mitozantrone up to 23mgm2 in combination with cyclophosphamide and 5-fluorouracil have been successfully administered with filgrastim support. At the maximum dose the limiting factor was still neutropenia (Catimel et al., 1992) .
With intensive chemotherapy it is important to find combinations of drugs that are suited to dose escalation, and it appears that the 3M combination is not the most suited to this. Although the number of patients in this phase I study is small, the response rate was noted to be in the range achieved with the 3M combination (Powles et al., 1991) and there was no evidence of a dose-response effect. In addition, the median duration of response was around 8 months, a figure that is achieved with most regimens for advanced disease. This suggests that patients with metastatic disease remain incurable and that current methods of dose escalation will do little to change the natural history of this stage of disease. In addition, although metastatic patients are often treated with novel agents to document toxicity and efficacy, the results may in fact be misleading as this group of patients tolerate treatment poorly and have inherently resistant disease. However, it will be ethically difficult to find any alternative strategy.
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